These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]. Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849 [TBL] [Abstract][Full Text] [Related]
11. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
13. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis. Hu W; Xu WS; Liao XF; He HJ Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Hurwitz HI; Tebbutt NC; Kabbinavar F; Giantonio BJ; Guan ZZ; Mitchell L; Waterkamp D; Tabernero J Oncologist; 2013; 18(9):1004-12. PubMed ID: 23881988 [TBL] [Abstract][Full Text] [Related]
16. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Los M; Roodhart JM; Voest EE Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
19. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893 [TBL] [Abstract][Full Text] [Related]
20. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Welch S; Spithoff K; Rumble RB; Maroun J; Ann Oncol; 2010 Jun; 21(6):1152-1162. PubMed ID: 19942597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]